TAU-2014-1: Phase I Trial of Mibefradil Dihydrochloride With Hypofractionated Re-Irradiation Therapy in Treating Patients With Recurrent Glioblastoma Multiforme (GBM)

Trial Profile

TAU-2014-1: Phase I Trial of Mibefradil Dihydrochloride With Hypofractionated Re-Irradiation Therapy in Treating Patients With Recurrent Glioblastoma Multiforme (GBM)

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Apr 2017

At a glance

  • Drugs Mibefradil (Primary)
  • Indications Glioblastoma
  • Focus Adverse reactions
  • Sponsors Cavion
  • Most Recent Events

    • 30 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 09 Jan 2017 Planned End Date changed from 1 Nov 2016 to 1 Mar 2018.
    • 09 Jan 2017 Planned primary completion date changed from 1 Nov 2016 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top